Cargando…

IFN-γ induces PD-L1 through p38/JNK/ERK signaling pathways and counteracts the tumor promoting effect mediated by PD-L1 in Glioblastoma

Glioblastoma is the most malignant primary glioma. Conventional treatment methods that include surgery, radiotherapy, and chemotherapy have a limited curative effect on the tumor. With the deepening of molecular biology research, molecular targeted therapy has opened a new era of tumor therapy. Prog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jia, Huafang, Xie, Xiaoli, Wang, Long, Wang, Lijuan, Che, Fengyuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259257/ https://www.ncbi.nlm.nih.gov/pubmed/35814563 http://dx.doi.org/10.1155/2022/5492602

Ejemplares similares

Superinduction of immunosuppressive glioblastoma extracellular vesicles by IFN-γ through PD-L1 and IDO1
por: Jung, Mi-Yeon, et al.
Publicado: (2022)

Increase of cells expressing PD‐1 and PD‐L1 and enhancement of IFN‐γ production via PD‐1/PD‐L1 blockade in bovine mycoplasmosis
por: Goto, Shinya, et al.
Publicado: (2017)

Abrogation of IFN-γ Signaling May not Worsen Sensitivity to PD-1/PD-L1 Blockade
por: Vackova, Julie, et al.
Publicado: (2020)

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
por: Qian, Jiawen, et al.
Publicado: (2018)

IFN-γ Induces PD-L1 Expression in Primed Human Basophils
por: Bonam, Srinivasa Reddy, et al.
Publicado: (2022)

PD-L1/PD-1 Axis in Glioblastoma Multiforme
por: Litak, Jakub, et al.
Publicado: (2019)

IFNγ/PD-L1 Signaling Improves the Responsiveness of Anti-PD-1 Therapy in Colorectal Cancer: An in vitro Study
por: Yuan, Wenli, et al.
Publicado: (2021)

Expression of PD-L1 on Canine Tumor Cells and Enhancement of IFN-γ Production from Tumor-Infiltrating Cells by PD-L1 Blockade
por: Maekawa, Naoya, et al.
Publicado: (2014)

IFN-γ surmounts PD-L1/PD1 inhibition to CAR-T cell therapy by upregulating ICAM-1 on tumor cells
por: Dong, E, et al.
Publicado: (2021)

PD-L1 upregulation by IFN-α/γ-mediated Stat1 suppresses anti-HBV T cell response
por: Liu, LanLan, et al.
Publicado: (2020)

IFN-γ-Stimulated Neutrophils Suppress Lymphocyte Proliferation through Expression of PD-L1
por: de Kleijn, Stan, et al.
Publicado: (2013)

Synergistic effect of IFN-γ and IL-1β on PD-L1 expression in hepatocellular carcinoma
por: Numata, Yasunao, et al.
Publicado: (2022)

IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
por: Abiko, K, et al.
Publicado: (2015)

MYC activation impairs cell-intrinsic IFNγ signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer
por: Alburquerque-Bejar, Juan J., et al.
Publicado: (2023)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

Interferon-γ induced PD-L1 expression and soluble PD-L1 production in gastric cancer
por: Imai, Yushi, et al.
Publicado: (2020)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

A secondary role for hypoxia and HIF1 in the regulation of (IFNγ-induced) PD-L1 expression in melanoma
por: van Duijn, Anneloes, et al.
Publicado: (2021)

Upregulation of PD-L1 Expression by Prostaglandin E(2) and the Enhancement of IFN-γ by Anti-PD-L1 Antibody Combined With a COX-2 Inhibitor in Mycoplasma bovis Infection
por: Goto, Shinya, et al.
Publicado: (2020)

Identification and Mechanism of the PD-1/PD-L1 Genomic Signature SORL1 as Protective Factor in Bladder Cancer
por: Xu, Yajing, et al.
Publicado: (2021)

Anti-PD1 up-regulates PD-L1 expression and inhibits T-cell lymphoma progression: possible involvement of an IFN-γ-associated JAK-STAT pathway
por: Xue, Weili, et al.
Publicado: (2019)

PD‐L1/PD‐L1 signalling promotes colorectal cancer cell migration ability through RAS/MEK/ERK
por: Cao, Yihui, et al.
Publicado: (2022)

EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
por: Fang, Wenfeng, et al.
Publicado: (2014)

PD-L1 Expression and Combined Status of PD-L1/PD-1–Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients
por: Han, Jiheun, et al.
Publicado: (2017)

PD-L1 Mediates IFNγ-Regulation of Glucose but Not of Tryptophan Metabolism in Clear Cell Renal Cell Carcinoma
por: Garige, Mamatha, et al.
Publicado: (2022)

Comprehensive analysis of PD-L1 expression in glioblastoma multiforme
por: Heiland, Dieter Henrik, et al.
Publicado: (2017)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

Antitumor Effect of Korean Red Ginseng through Blockade of PD-1/PD-L1 Interaction in a Humanized PD-L1 Knock-In MC38 Cancer Mouse Model
por: Lee, Eun-Ji, et al.
Publicado: (2023)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

Complement C5a induces PD-L1 expression and acts in synergy with LPS through Erk1/2 and JNK signaling pathways
por: An, Ling-Ling, et al.
Publicado: (2016)

PB2476: TARGETING OF BRD4 TO COUNTERACT CYTOKINE-INDUCED EXPRESSION OF PD-L1 AND PD-L2 ON VASCULAR, OSTEOBLASTIC AND STROMAL NICHE CELLS
por: Filik, Yüksel, et al.
Publicado: (2023)

CD137 ligand feedback upregulates PD‐L1 expression on lung cancer via T cell production of IFN‐γ
por: Wang, Helin, et al.
Publicado: (2019)

Bidirectional crosstalk between epithelial–mesenchymal plasticity and IFNγ-induced PD-L1 expression promotes tumour progression
por: Burger, Gerhard A., et al.
Publicado: (2022)

Dynamical modelling of proliferative-invasive plasticity and IFNγ signaling in melanoma reveals mechanisms of PD-L1 expression heterogeneity
por: Subhadarshini, Seemadri, et al.
Publicado: (2023)

Dynamical modeling of proliferative-invasive plasticity and IFNγ signaling in melanoma reveals mechanisms of PD-L1 expression heterogeneity
por: Subhadarshini, Seemadri, et al.
Publicado: (2023)

IFNγ induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma
por: Moon, Ji Wook, et al.
Publicado: (2017)

PD-1(+) IFN-γ(+) subset of CD8(+) T cell in circulation predicts response to anti–PD-1 therapy in NSCLC
por: Chen, Wenxiu, et al.
Publicado: (2023)

Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
por: Shen, Xian, et al.
Publicado: (2018)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3tuq3ecrno9p1541o03joe2oco